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Background: Realizing constructive applications of synthetic biology requires continued development of enabling
technologies as well as policies and practices to ensure these technologies remain accessible for research. Broadly
defined, enabling technologies for synthetic biology include any reagent or method that, alone or in combination
with associated technologies, provides the means to generate any new research tool or application. Because
applications of synthetic biology likely will embody multiple patented inventions, it will be important to create
structures for managing intellectual property rights that best promote continued innovation. Monitoring the
enabling technologies of synthetic biology will facilitate the systematic investigation of property rights coupled to
these technologies and help shape policies and practices that impact the use, regulation, patenting, and licensing
of these technologies.
Results: We conducted a survey among a self-identifying community of practitioners engaged in synthetic biology
research to obtain their opinions and experiences with technologies that support the engineering of biological
systems. Technologies widely used and considered enabling by survey participants included public and private
registries of biological parts, standard methods for physical assembly of DNA constructs, genomic databases,
software tools for search, alignment, analysis, and editing of DNA sequences, and commercial services for DNA
synthesis and sequencing. Standards and methods supporting measurement, functional composition, and data
exchange were less widely used though still considered enabling by a subset of survey participants.
Conclusions: The set of enabling technologies compiled from this survey provide insight into the many and varied
technologies that support innovation in synthetic biology. Many of these technologies are widely accessible for use,
either by virtue of being in the public domain or through legal tools such as non-exclusive licensing. Access to
some patent protected technologies is less clear and use of these technologies may be subject to restrictions
imposed by material transfer agreements or other contract terms. We expect the technologies considered enabling
for synthetic biology to change as the field advances. By monitoring the enabling technologies of synthetic biology
and addressing the policies and practices that impact their development and use, our hope is that the field will be
better able to realize its full potential.
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Synthetic biology is an emerging, interdisciplinary field
that aims to make the design, construction, and optimi-
zation of biological systems easier and more reliable.
Advances in synthetic biology will deepen our under-
standing of how biological systems work, and should
enable faster and cheaper development of useful medi-
cines, chemicals and materials, new means for informa-
tion processing and data storage, and sources of food
and energy that could help promote human health and
preserve the environment. Although the field of syn-
thetic biology is relatively young, there have already been
promising advances in engineering microorganisms to
produce important drugs [1,2], exploring strategies for
biofuel production [3,4], and designing and DNA-based
information storage [5,6] and genetically-encoded com-
munications and processing systems [7,8].
As is true for many emerging fields of research, realiz-
ing the full potential for constructive applications of
synthetic biology will require not only the continued
development of enabling technologies but also the im-
plementation of policies and practices to ensure that
these technologies remain accessible to those working in
basic and applied research. The enabling technologies
for synthetic biology can be defined, broadly, as any re-
agent or method that, alone or in combination with as-
sociated technologies, provides the means to generate
any new research tool or application in synthetic biology.
Because the field of synthetic biology spans a wide range
of disciplines – from engineering and biology to math-
ematics and computer science – the technologies con-
sidered “enabling” by synthetic biology researchers may
be expected to cover a broad range, depending on the
focus and nature of the research. Monitoring the enab-
ling technologies of synthetic biology is an important
step towards understanding the needs, abilities and ac-
complishments of this diverse research community.
Here, we conducted a survey among a self-identifying
community of practitioners engaged in synthetic biology
research to obtain their opinions and experiences with
technologies that support the engineering of biological
systems. The aim of this first study was to define a set of
enabling technologies for the field of synthetic biology,
with a focus on technologies used in research laborator-
ies in both academia and industry. Our goal was to
gather information about the technologies considered
enabling by practitioners in the field so that we and
others might better evaluate the landscape of synthetic
biology and explore policies and practices that best pro-
mote continued innovation. For example, it is likely that
useful applications of synthetic biology will embody mul-
tiple patented inventions and monitoring the enabling
technologies of synthetic biology will facilitate the sys-
tematic investigation of the intellectual property rightscoupled to those technologies. Investors and funders of
synthetic biology research also may find this information
useful in guiding funding decisions and establishing pol-
icies for the patenting and licensing of enabling technolo-
gies. Information gained from monitoring the enabling
technologies of synthetic biology also may be useful in
identifying technology trends, and could help government
agencies and non-governmental organizations in crafting
policy frameworks to address the safety and security con-
cerns raised by synthetic biology research.
Results
Demographic data
During the period the survey was active, from August
31, 2012 to January 30, 2013 a total of 160 responses
were received. Six responses were excluded because they
did not contain answers to any of the substantive ques-
tions on technology use. Seventeen responses were from
participants who answered “no” to Survey Question 11
that asked survey participants to indicate whether they
considered themselves to be a synthetic biologist or to
be engaged in basic or applied synthetic biology research
or development. Responses from these 17 survey partici-
pants were analyzed separately, and the remaining 137
responses were used for most analyses.
Responses originated from the United States (121 re-
sponses, 88%) and ten other countries (16 responses,
12%). The distribution of responses from outside the
United States was Australia (1), Canada (1), Germany (2),
Israel (1), Italy (1), Japan (3), Mexico (1), Sweden (1), and
the United Kingdom (5). Responses were received from
researchers working exclusively in a non-commercial
organization (n = 91, 66%), exclusively in a commercial
organization (n = 39, 28%) and in both commercial and
non-commercial organizations (n = 7, 5%). Among survey
respondents working exclusively in a non-commercial
organization, most indicated that they worked in a college
or university (n = 64), research institution (n = 9), govern-
ment laboratory (n = 1), were affiliated with both a col-
lege/university and research institution (n = 12) or were
independent (n = 5). Among survey respondents working
exclusively in a commercial organization, most were from
small companies of fewer than 50 employees (n = 21) and
the rest were from companies of more than 1000 em-
ployees (n = 11), fewer than 1000 employees (n = 3), and
fewer than 250 employees (n = 4). Of the 7 survey respon-
dents that worked in both commercial and non-commer-
cial organizations, all worked in a small company of fewer
than 50 employees as well as a college/university or re-
search institution.
Experience with the iGEM competition
Survey Question 2 asked participants to provide infor-
mation about their experience as student or non-student
Figure 1 Publicly available registries of natural or engineered
biological materials or information. (A) Percentage of synthetic
biology researchers in academia that use biological parts from, or
contribute parts to, publicly available registries. (B) Percentage of
synthetic biology researchers in industry that use biological parts
from, or contribute parts to, publicly available registries. (C) Impact
of iGEM experience on use of the iGEM Registry by synthetic biology
researchers in academia and industry.
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Machines (iGEM) competition (http://igem.org), a syn-
thetic biology competition aimed at undergraduate stu-
dents, high school students, and entrepreneurs. Of the
136 survey participants that responded to this question,
112 (82%) indicated that they did not participate in the
iGEM competition as a student, 21 (15%) indicated that
they previously participated in the iGEM competition as
a student, and 3 (2%) indicated that they were a student
currently participating in the iGEM competition.
In addition, 58 survey participants provided free-text
responses describing their experience as non-student
participants of the iGEM competition. Of these, 49
stated that they had advised or mentored iGEM teams
or served as judges for the iGEM competition, 6 sup-
ported or sponsored iGEM teams, and 3 stated that they
had other experience with the iGEM competition, in-
cluding participating in organizing the software division,
assisting in evaluation of the iGEM program, and read-
ing iGEM research reports Thirteen of the 58 survey
participants who provided free-text responses were also
former students of the iGEM competition, while 45 had
no prior experience with iGEM as students.
Use of publicly available registries
Survey Question 3 asked participants to indicate whe-
ther they used publicly available registries to obtain nat-
ural or engineered biological materials or information.
This question allowed survey participants to select from
a list of publicly available registries and to write in any
additional registries of which they were aware. The listed
registries included publicly available collections of infor-
mation (including DNA sequences) or tangible materials
that could be used for synthetic biology research, includ-
ing plasmids encoding specific biological functions,
DNA-binding proteins, microorganisms and cell lines
(hereinafter referred to as biological parts). Specifically,
the publicly available registries initially listed included
the Registry of Standard Biological Parts supporting the
iGEM competition (iGEM Registry), the American Type
Culture Collection (ATCC), Addgene, the Coli Genetic
Stock Center (CGSC), the Synthetic Biology Enginee-
ring Resource Center (SynBERC) Registry, the Joint
BioEnergy Institute Public Registry (JBEI-ICE Public),
the European Saccharomyces cerevisiae Archive for
Functional Analysis (EUROSCARF), the Agricultural
Research Service NRRL collection (ARS/NRRL), the
BIOFAB: International Open Facility Advancing Biotech-
nology (BIOFAB), the Dana-Farber/Harvard Cancer
Center (DF/HCC) PlasmID Repository, the DNASU
Plasmid Repository (DNASU), the Belgian Coordinated
Collections of Micro-organisms (BCCM), and the
Leibniz-Institut DSMZ - German Collection of Microor-
ganisms and Cell Cultures (DSMZ).The majority of synthetic biology researchers in academia
(n = 88) used biological parts from or contributed parts to
the iGEM Registry (n = 60, 68%) and the ATCC (n = 53,
60%), and many used or contributed to Addgene (n = 42,
48%) (Figure 1A). Other publicly available registries that
were widely used among academic researchers included the
CGSC (n = 18, 20%), the SynBERC Registry (n = 13, 15%),
JBEI-ICE Public (n = 11, 12%) and EUROSCARF (n = 8,
9%). Fewer researchers in academia reported use or contri-
bution of parts to the ARS/NRRL (n = 5), the BIOFAB
Figure 2 Private registries of natural or engineered biological
materials or information. Percentage of synthetic biology
researchers in academia and industry that maintain a private registry
of biological parts, make these materials available to others, send
materials to others directly, and send materials via a publicly
available registry.
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DSMZ (n = 1), and the BCCM (n = 1). Additional regis-
tries identified by academic researchers included the
CyanoBase-Kazusa Genome Resources (http://www.ncbi.
nlm.nih.gov/pmc/articles/PMC2808859) (n = 1), and the
various yeast collections distributed by Invitrogen (n = 1).
Synthetic biology researchers in industry (n = 39)
reported different usage rates for publicly available regis-
tries (Figure 1B). The majority of industry researchers
used or contributed parts to the ATCC (n = 26, 67%),
and many used or contributed parts to the iGEM Regis-
try (n = 18, 46%). Other publicly available registries used
by industry researchers included Addgene (n = 12, 31%),
the CGSC (n = 9, 23%), the SynBERC Registry (n = 4,
10%), the JBEI-ICE Public (n = 3, 8%) and the ARS/
NRRL (n = 4, 10%). Fewer industry researchers reported
use or contribution of parts to the EUROSCARF (n = 2),
the BCCM (n = 1), and the DSMZ (n = 2). Additional
registries identified by industry researchers included the
Keio/ASKA collection of E. coli strains (http://www.
shigen.nig.ac.jp/ecoli/strain/top/top.jsp) (n = 1) and the
pZ series expression vectors developed by Lutz and
Bujard [9] (http://www.expressys.com) (n = 1).
Among the publicly available registries included in this
survey, only the iGEM Registry showed a statistically sig-
nificant difference in usage rates between researchers in
academia and industry (p = 0.03). This difference was
explored further by examining the impact of prior iGEM
experience on use of the iGEM Registry (Figure 1C).
Among synthetic biology researchers in academia, those
having experience with the iGEM competition either as
a student or non-student participant (e.g., advisors,
judges, sponsors, etc.) were significantly more likely to
contribute parts to or use parts from the iGEM Registry
as compared to academic researchers without iGEM
experience (93% and 46%, respectively, p < 0.00001).
Similarly, industry researchers having experience with
the iGEM competition were significantly more likely to
use or contribute parts to the iGEM Registry than indus-
try researchers lacking iGEM experience (65% and 26%,
respectively, p = 0.02). Academic researchers having
iGEM experience also were significantly more likely than
industry researchers with iGEM experience to use or
contribute to the iGEM Registry (93% and 65%, respect-
ively, p < 0.01). No significant difference was observed
in use of the iGEM Registry between academic and in-
dustry researchers without iGEM experience (46% and
26%, p = 0.17).
Use of private registries
Survey Question 4 asked participants to indicate whe-
ther the laboratories or organizations in which they
worked maintained a private registry of biological parts,
and whether and how these parts were made available toothers. Most synthetic biology researchers in academia
reported that the laboratory or organization in which
they worked maintained its own registry of biological
parts (55/88, 62%) (Figure 2). Of these, the vast majority
of academic researchers made these materials available
to others outside their own laboratory (53/55, 96%). A
significantly greater proportion of academic researchers
sent parts directly to others (40/53, 75%) as compared to
those that distributed parts through a publicly available
registry (15/53, 28%) (p < 0.00001).
Similarly, most synthetic biology researchers in indus-
try reported that the laboratory or organization in which
they worked maintained its own registry of biological
parts (21/39, 54%). However, fewer than half of industry
researchers made these parts available to others (9/21,
43%). A significantly greater proportion of industry
researchers also sent materials directly to others (6/9,
67%) as opposed to distributing parts through a publicly
available registry (1/9, 11%) (p = 0.05).
A comparison of the use and distribution rates be-
tween academic and industry researchers revealed no
statistically significant difference in the likelihood of
maintaining a private registry of biological parts (p =
0.43). However, researchers in academia were signifi-
cantly more likely to make parts available to others than
researchers in industry (p < 0.000001).Favorite or most useful biological parts
A total of 43 participants responded to Survey Question
5, which was an open question asking respondents to list
their favorite or most useful biological parts (Table 1).
Biological parts that survey participants identified in
more general terms included the Anderson promoter li-
brary (n = 4), in-house promoters (n = 2), three-color
Table 1 Favorite or most useful biological parts from publicly available registries
ID Category N Description
Addgene
25712:pAKTaq Plasmid 1 Bacterial expression vector encoding the DNA
polymerase from Thermus aquaticus
Coli Genetic Stock Center
CGSC #12119 Chassis 1 E. coli strain BW27783 bearing 9 known mutations
iGEM Registry
BBa_J23100 series Regulatory 8 BBa_J23100 through BBa_J23119 is a family of constitutive
promoter parts that can be used to tune the expression
level of constitutively expressed parts
BBa_B0034 RBS 4 RBS based on Elowitz & Liebler repressilator
BBa_B0015 Terminator 1 Double terminator including BBa_B0010 and BBa_B0012
BBa_C0062 Coding 1 luxR repressor/activator
BBa_E2050 Coding 1 derivative of mRFP1, yeast-optimized
BBa_F2620 Signaling 1 A signaling device whereby the input is 3OC6HSL and
the output is PoPS from a LuxR-regulated operator
BBa_I15010 Coding 1 Chimeric Cph1 light receptor/EnvZ protein
BBa_I744210 Generator 1 TetR regulated LuxN-Tsr Chimeric Receptor B
BBa_J04450 Reporter 1 RFP coding device
BBa_J15001 RBS 1 strong synthetic E. coli RBS with SacI site
BBa_J153000 Plasmid Backbone 1 broad-host-range shuttle vector pPMQAK1 that provides
ampicillin and kanamycin/neomycin resistance
BBa_J176005 Protein Domain 1 Codon optimized mCherry red fluorescent protein
BBa_J176006 Coding 1 Mammalian venus fluorescent protein
BBa_J176022 Protein Domain 1 Human codon-optimized AmCyan1 from pAmCyan1-C1
BBa_J33207 Reporter 1 lac promoter and lacZ
BBa_J61009 Plasmid 1 pAC-LuxGFP that places GFP under the wildtype
Vibrio lux device
BBa_J64032 Device 1 pCASP SPI-1 Secretion Circuit
BBa_J85226 Composite 1 Kanamycin resistance (KanR)_off version of J85224
BBa_J176027 Regulatory 1 Constitutive cytomegalovirus promoter
BBa_J176122 Plasmid Backbone 1 pcDNA3.1 plus puromycin resistance
BBa_K566002 Regulatory 1 Biphasic switch
BBa_P1010 Generator 1 ccdB cell death gene
BBa_R0040 Regulatory 1 TetR repressible promoter
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dependent promoters (n = 1), BIOFAB promoters (n =
1), fluorescent proteins (n = 9), colored proteins made at
DNA2.0 (n = 1), all the working reporters in the iGEM
Registry (n = 1), BioBrick vectors (n = 2), pRS vector
series (n = 1), pZ vectors (n = 1), vectors (n = 1), high
copy plasmid backbones from the iGEM Registry (n =
1), bicistronic design parts (n = 1), quorum sensing parts
(n = 1), terminator variants (n = 1), and TetR (n = 2).
Use of physical assembly standards and methods
Survey Question 6 asked participants to indicate their
current and past use of physical assembly standards andmethods. This question allowed survey participants to
select from a list of physical assembly methods and to
write in any additional assembly methods that they used.
Of the 134 survey participants that answered this ques-
tion, most indicated that they currently use or previously
have used the Gibson assembly method (48% current,
22% past) and de novo DNA synthesis (50% current, 18%
past) (Figure 3). The original BioBrick standard (18%
current, 31% past) and Gateway cloning (15% current,
26% past) were selected by a significant number of sur-
vey participants, although most indicated past use of
these specific methods. Survey participants indicated
lower overall usage rates for other physical assembly
Figure 3 Physical assembly standards and methods. Current and
past use of physical assembly standards and methods by synthetic
biology researchers.
Table 2 Additional physical assembly methods identified
by survey participants
Physical Assembly Method N
Commercial/Proprietary
Proprietary method, not specified 3
GeneArt Seamless Assembly 2
GeneArt High Order Assembly 1
Clontech In-Fusion HD cloning kit 1
Ginkgo assembly method 1
Invitrogen TOPO cloning 1
Non-Commercial
Conventional PCR [10,11] 10
Yeast in vivo recombinational cloning [12] 5
Home-brew method, not specified 4
Restriction-site Associated DNA (RAD) assembly [13] 2
Anderson 2 antibiotic (2ab) assembly [14] 1
Inverse PCR [15] 1
Splicing by Overlap Extension (SOE) [16] 1
In development
A new enzymatic, scarless synthesis and assembly technology 1
Extensions of BioBytes assembly standard [17] 1
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16% past), Sequence and Ligase Independent Cloning
(SLIC) (14% current, 21% past), GoldenGate (16%
current, 10% past), and others.
In addition to the physical assembly methods listed in
Question 6, survey participants providing free-text re-
sponses to this question (n = 33) identified additional as-
sembly methods that they used in the course of
synthetic biology research (Table 2).Figure 4 Standards and methods for measurement, functional
composition, and data exchange. Current and past use of
standards and methods for measurement, functional composition,
and data exchange by synthetic biology researchers.Use of measurement, functional composition and data
exchange standards and tools
A total of 120 and 127 survey participants responded to
Survey Questions 7 and 8, respectively, which asked re-
spondents to indicate their current or past use of meas-
urement tools, functional composition standards, and
data exchange tools. These questions allowed survey
participants to select from a list of tools and to write in
any additional measurement, functional composition
and data exchange tools that they used. Usage rates for
measurement standards, functional composition stan-
dards, and data exchange standards were relatively low
(Figure 4). Specifically, the number of survey respon-
dents reporting current and past use were: Relative Pro-
moter Unit (RPU) (7% current, 14% past), Polymerase
Per Second (PoPS) (2% current, 14% past), Relative
Mammalian Promoter Unit (RMPU) (0 current, 2%
past), Expression Operating Unit (EOU) (4% current, 3%
past), Synthetic Biology Open Language (SBOL) (18%
current, 10% past), SBOL visual (SBOLv) (16% current,
3% past), JBEI-ICE repository platform (8% current, 2%
past), electronic datasheets (7% current, 7% past), and
visual datasheets (4% current, 4% past).Additional measurement tools identified by survey partic-
ipants included fluorescence reporter protein measurement
(n = 4), Miller assay (n = 2), beta-galactosidase assay
(n = 2), cell auto-fluorescence (n = 1), dual-luciferase re-
porter measurement (n = 1), comprehensive metabolite
measurement (n = 1), comprehensive proteome (n = 1),
specific mRNA or protein measurements (n = 1), RNAseq
(n = 1), and qPCR (n = 1). Additional data exchange tools
included custom laboratory management information sys-
tems (n = 2), JERM (n = 1), RightField (n = 1), Systems
Biology Markup Language (SMBL) (n = 1), GoogleDocs
(n = 1), and the GenBank file format (n = 1).
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Survey Question 9 asked participants to indicate their
current and past use of additional tools, reagents, and
methods. This question allowed survey participants to
select from a list and to write in any other tool reagent
or method that they considered enabling for the field of
synthetic biology. Of the survey participants that
responded to this question, the vast majority indicated
that they used GenBank as their preferred genomic data-
base (84% current, 12% past) and employed tools for
search (84% current, 15% past), alignment (78% current,
16% past), and analysis (68% current, 13% past) of DNA
sequences (Figure 5). Most survey participants used
commercial DNA synthesis services for short oligos
(86% current, 11% past) and gene-size fragments (71%
current, 12% past), while fewer researchers used in-
house DNA synthesis for short oligos (14% current, 15%
past) and gene-size fragments (26% current, 44% past).
The vast majority of survey participants indicated that
they used established culture techniques, as well as other
established technologies such as the polymerase chainFigure 5 Additional tools, reagents and methods. Current and
past use of genomic databases, sequence tools, DNA synthesis tools,
DNA sequencing tools, culture techniques, and other tools, reagents,
and methods by synthetic biology researchers.reaction (PCR), green fluorescent protein (GFP), and
non-GFP reporter molecules, while fewer researchers
used newer techniques such as directed evolution (e.g.,
MAGE) (22% current, 10% past).
In addition to the tools, reagents and methods that
were listed, survey participants providing free text re-
sponses (n = 23) identified additional technologies that
they considered enabling for synthetic biology (Table 3).Use of software tools
A total of 133 survey participants responded to Survey
Question 10, which asked participants to indicate their
current and past use of software tools. This question
allowed survey participants to select software tools that
were listed and to write in any additional software tools
they used. The highest rates of current use were reported
for ApE (41% current, 24% past), Primer 3 (33% current,
24% past), Mfold (34% current, 21% past), and the Ribo-
some Binding Site (RBS) Calculator (28% current, 28%
past) (Figure 6). Vector NTI (17% current, 51% past),
GeneDesigner (22% current, 27% past), and Mathematica
(11% current, 35% past) were selected by a significant
number of survey participants, although most indicated
past use of these software tools. Lower but increasing-over
-time usage rates were reported for the j5 DNA Assembly
(16% current, 9% past), Genome Compiler (11% current,
6% past), and GenoCAD (10% current, 6% past) software
tools. In addition to the software tools that were listed,
survey participants providing free text responses (n = 36)
identified additional software tools used in the course of
their synthetic biology research (Table 4).Technology choices and self-identification as a synthetic
biologist
Survey Question 11 asked participants whether they
considered themselves to be a synthetic biologist or to
be engaged in basic or applied synthetic biology research
or development. Because this question was introduced
on Day 6 of the survey, not all participants were able to
respond to this question. A total of 58 survey partici-
pants had submitted responses prior to Day 6 and
because all of these participants were students or post-
doctoral fellows in the Endy or Smolke labs or re-
searchers affiliated with SynBERC they were considered
to be synthetic biology researchers for the purposes of
the survey. Of the 96 survey participants that submitted
responses on Day 6 and later, 79 answered “yes” and 17
answered “no” to this question. Responses from the 79
participants that affirmatively self-identified as synthetic
biologists and the 58 participants that responded prior
to Day 6 were grouped together for most analyses. Re-
sponses from the 17 participants that did not self-
identify as synthetic biologists were analyzed separately.
Table 3 Additional technologies considered enabling for synthetic biology by survey participants
Tool, Reagent or Method Description (URL or reference) N
BioCyc a collection of 1962 pathway and genome databases (http://biocyc.org) 1





a technology that permits the hierarchical consolidation of modified genomic regions [18] 1
High Throughput Computing the ability to run many copies of software at the same time across many different computers,
reviewed in [19]
1
in vitro screens tests for biological activity such as metal binding screens, electron uptake, and other enzymatic activity 2
IonTorrent an approach to DNA sequencing that enables a direct connection between chemical and digital
information and aims to place DNA sequencing within the reach of any laboratory or clinic [20]
1
EcoCyc a database for Escherichia coli K-12 MG1655 (http://ecocyc.org) 1
Flow Cytometry a technology that uses the principles of light scattering, light excitation, and emission of fluorochrome
molecules to generate specific multi-parameter data from particles and cells in the size range of 0.5 μm to
40 μm diameter (http://crl.berkeley.edu/flow_cytometry_basic.html)
3
KEGG: Kyoto Encyclopedia of Genes
and Genomes
a database resource for understanding high-level functions and utilities of the biological system, such as
the cell, the organism and the ecosystem, from genomic and molecular-level information (http://www.
genome.jp/kegg)
1
Mass spectrometry a technology for targeted protein quantification, reviewed in [21] 2
MetaCyc a database of nonredundant, experimentally elucidated metabolic pathways (http://metacyc.org) 1
Molecular biology technologies,
generally
includes methods and reagents for creating competent cells, nucleic acid transfer, digestion, primer
extension, ligation, assembly of DNA molecules, etc.
9
OptForce an algorithm that identifies all possible metabolic interventions that lead to the overproduction of a
biochemical of interest [22]
1
PDB: Protein DataBank an information portal to biological macromolecular structures (http://www.rcsb.org/pdb/home/home.do) 1
Protein purification technologies methods for purifying a protein of interest efficiently, reviewed in [23] 1
Recombineering an in vivo method of genetic engineering applicable to chromosomal and episomal replicons
in E. coli [24]
1
Robotic automation use of robots for repetitive laboratory tasks such as pick and place, liquid and solid additions, heating,
cooling, mixing, shaking, etc.
2
Single cell microscopy a technology that enables visualization of gene expression with exquisite spatial and temporal sensitivity,
reviewed in [25]
1
Standards, needed includes standards for calibrating and sharing data from plate readers, standards for test, measurement
and characterization, standards for documentation and sharing of biological modules, for example see
Arkin, 2008 [26] and Endy, 2005 [27]
3
SOLiD a next generation sequencing technology that allows identification of hundreds of millions of short RNAs




a technology that allows proteins to be designed to specifically target and bind to a desired sequence
of DNA [29]
1
UniProt: Universal Protein Resource a collaboration between the European Bioinformatics Institute (EBI), the SIB Swiss Institute of
Bioinformatics and the Protein Information Resource (PIR) that aims to provide a comprehensive resource
for protein sequence and annotation data (http://www.uniprot.org)
1
Yeast in vivo recombination methods for assembling large DNA constructs in the yeast Saccharomyces cerevisiae, for example see
Gibson et al., 2008 [30] and Jaschke et al., 2012 [31]
1
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thetic biologists, 12 were from the US, 2 were from the
UK, 1 was from Austria, 1 was from Norway, and 1 was
from Portugal. Eleven participants worked exclusively in
non-commercial organizations – 5 in a college or uni-
versity, 2 in a research institution, 1 in both a college/
university and research institution, and 3 were independ-
ent. The remaining 6 worked exclusively in commercial
organizations – 3 in a company with more than 1,000employees, 2 in a company of fewer than 50 employees,
and 1 in a company of fewer than 250 employees.
Twelve of the 17 participants had no experience with
the iGEM competition, 1 had been a sponsor for iGEM
teams, and 1 collaborated with an iGEM team as a DIY
biologist.
Among the 17 participants who did not self-identify as
synthetic biologists, two indicated that they used parts
from the iGEM Registry (one was a former iGEM
Figure 6 Software tools. Current and past use of software tools by
synthetic biology researchers.
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some participants used parts from other publicly avail-
able registries, including the ATCC (n = 5), Addgene
(n = 3), the ARS/NRRL (n = 2), the BIOFAB (n = 1), and
the CGSC (n = 1). With regards to private registries, 4
participants (3 from academia, 2 from industry) indi-
cated that the laboratories or organizations in which
they worked maintained a private registry of biological
parts. Of these, 3 made parts available to others (all from
academia) – 3 by sending parts directly, and 1 by also
distributing parts through a publicly available registry.
None of these 17 participants reported current use of
standards and methods for measurement, functional
composition, or data exchange, although past use of the
RPU (n = 1), electronic datasheets (n = 1), and visual
datasheets (n = 1) was noted. Both current and past use
was reported for other technologies covered in this sur-
vey, including physical assembly methods, software tools,
and other tools, reagents, and methods (Table 5).
Discussion
The emerging field of synthetic biology has captured the
interest and energy of researchers from a variety of
disciplines – biology, chemistry, computer science,engineering, and more. Our survey tapped the experi-
ences and perspectives of this diverse research commu-
nity in order to glean initial insights into the
technologies that are considered enabling for the field by
its practitioners. The results of the survey offer a first
snapshot view of the technologies previously and now in
use by synthetic biology researchers, and give a sense of
the many and varied technologies that support work in
synthetic biology.
One of our objectives in conducting this survey was to
establish a set of technologies considered enabling for
the field of synthetic biology, so that we and others
might systematically investigate the intellectual property
rights coupled to these technologies. For example, one
overall consideration regarding enabling technologies
and property rights is whether or not these technologies
are accessible for use – either by virtue of being in the
public domain or through legal tools such as non-
exclusive licensing – to researchers in academic, govern-
ment, and commercial organizations. The extent to
which innovation in synthetic biology, and biotechnol-
ogy more generally, may be impeded by broad founda-
tional patents that cannot be licensed or patent thickets
remains unclear [32-36]. Identifying the technologies to
which wide, unrestricted access is needed to promote
continued innovation in synthetic biology is an import-
ant step towards understanding the impact of patenting
and licensing practices on access to the enabling tech-
nologies underlying this field.
Consistent with the postulate that past scientific
achievements lay the foundation for future innovation,
the results of the survey showed that many of the tech-
nologies that enable research in synthetic biology are
well established and in the public domain. For many of
these earlier technologies patent protection was either
not sought or, even if patent protected, sufficient time
has lapsed for the technologies to enter the public do-
main. For example, the vast majority of survey respon-
dents reported use of bacterial cell culture technologies
such as LB medium or glycerol freezing (Figure 5), yet
these technologies were published in the scientific litera-
ture as early as the 1950’s [37-39] and are squarely in
the public domain. Similarly, the vast majority of survey
respondents reported use of PCR technology, yet ele-
ments of PCR technology have entered the public
domain or will do so shortly. Specifically, foundational
patents covering amplification methods (e.g., US
4,683,195 and EP 0 200 362 B), thermal cycling instru-
ments (e.g., US 5,038,852 and EP 0 395 736 B), and
thermostable DNA polymerases (e.g., US 4,889,818 and
EP 0 258 017 B) have now expired. Although patents
continue to be filed on improvements to PCR technolo-
gies, many subsequent patents such as those covering
thermostable polymerases with enhanced activities (e.g.
Table 4 Additional software tools used for synthetic biology research by survey participants
Software tool Description (URL) N
ABySS: Assembly By Short
Sequences
a de novo, parallel, paired-end sequence assembler that is designed for short reads
(http://www.bcgsc.ca/platform/bioinfo/software/abyss)
1
AlignDNA a pairwise DNA alignment tool (http://www.geneinfinity.org/sms/sms_aligndna.html) 1
BLAST: Basic Local Alignment
Search Tool
a program that finds regions of local similarity between biological sequences (http://blast.ncbi.nlm.nih.gov) 7
CentroidFold a program that predicts an RNA secondary structure from an RNA sequence (http://www.ncrna.org/centroidfold) 1
CLC Genomics Workbench a comprehensive and user-friendly analysis package for analyzing, comparing, and visualizing next generation
sequencing data (http://www.clcbio.com/products/clc-genomics-workbench)
5
CodonCode Aligner a program for sequence assembly, contig editing, and mutation detection (http://www.codoncode.com/aligner) 1
Cytoscape an open source software platform for visualizing and integrating complex networks (http://www.cytoscape.org) 1
FastPCR a program for PCR primer design (http://en.bio-soft.net/pcr/FastPCR.html) 1
Gene Construction Kit a program for plasmid mapping (http://www.textco.com/gene-construction-kit.php) 1
Geneious a program for handling and managing bioinformatics data (http://www.geneious.com) 7
Gibthon Ligation Calculator a software tool for calculating reactant concentrations for DNA ligation (http://django.gibthon.org/tools/ligcalc) 1
JWS online a tool for simulation of kinetic models from a curated model database (http://jjj.biochem.sun.ac.za) 1
Lasergene-DNAStar comprehensive software for DNA and protein sequence analysis, contig assembly and sequence project
management (http://www.dnastar.com)
7
Mascot a search engine which uses mass spectrometry data to identify proteins from primary sequence databases
(http://www.matrixscience.com/search_intro.html)
1
Mauve a system for efficiently constructing multiple genome alignments in the presence of large-scale evolutionary
events such as rearrangement and inversion (http://gel.ahabs.wisc.edu/mauve)
1
Merlin a M.A.G.E. optimization tool developed by the Cross-disciplinary Integration of Design Automation Research
group at Boston University (http://cidar1.bu.edu:8080)
1
OligoAnalyzer software for comprehensive oligonucleotide analysis (http://www.idtdna.com/analyzer/Applications/
OligoAnalyzer)
1
ORF Finder: Open Reading
Frame Finder
a graphical analysis tool which finds all open reading frames of a selectable minimum size in a user’s sequence
or in a sequence already in the database (http://www.ncbi.nlm.nih.gov/projects/gorf)
1
PaR-PaR software that allows researchers to use liquid-handling robots effectively (http://prpr.jbei.org) 1
Pigeon Synthetic Biology Open Language picture generator (http://cidar1.bu.edu:5801/pigeon1.php) 1
PlasMapper software that automatically generates and annotates plasmid maps using only the plasmid DNA sequence as
input (http://wishart.biology.ualberta.ca/PlasMapper)
1
PyMOL a user-sponsored molecular visualization system for rendering and animating 3D molecular structures on an
open-source foundation (http://pymol.org)
1
RNAstructure a complete package for RNA and DNA secondary structure prediction and analysis (http://rna.urmc.rochester.
edu/RNAstructure.html)
1
Serial Cloner freeware with an intuitive interface that assists in DNA cloning, sequence analysis and visualization
(http://serialbasics.free.fr/Serial_Cloner.html)
3
Sequencher DNA sequencing software (http://genecodes.com/sequencher-features) 1
SSC: Stochastic Simulation
Compiler
a tool for creating exact stochastic simulations of biochemical reaction networks (http://web.mit.edu/irc/ssc) 1
SWISS-PDB viewer (aka
DeepView)
an application that provides a user friendly interface allowing analysis of several proteins at the same time
(http://spdbv.vital-it.ch)
1
Synbiota a platform of collaborative services to design, store, post, organize, access, or share information
(https://mozillalabs.com/en-US/synbiota)
2
Velvet a set of algorithms to manipulate de Bruijn graphs for genomic sequence assembly (http://www.ebi.ac.uk/
~zerbino/velvet)
1
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are due to expire within the next year.
Other more recently developed technologies used by
synthetic biology researchers are currently patentprotected or have patent applications pending, yet are
accessible through non-exclusive licensing. For example,
the majority of survey respondents reported current or
past use of the Gibson assembly method [40] for in vitro
Table 5 Technologies used by survey participants that did not self-identify as synthetic biologists (n = 17)
Tool, reagent or method Current use Past use Tool, reagent or method Current use Past use
Physical assembly methods Genomic database
Gateway recombinatorial cloning 4 1 GenBank 10 3
de novo DNA synthesis 3 2 E!EnsemblGenomes 7 3
Gibson assembly 3 1 MicrobesOnline 3 1
Conventional restriction site-based cloning 2 0 European Nucleotide Archive 2 2
CPEC 1 2 DNA Databank of Japan 2 0
SLIC 1 1 Sequence tools
PIPE 1 1 Search (e.g., BLAST) 12 3
USER 1 1 Alignment (e.g., ClustalW2) 10 1
InFusion cloning 1 0 Analysis (e.g., OligoCalc) 7 2
RAD assembly 1 0 Software tools
Transfer PCR 1 0 ApE 6 1
Yeast in vivo cloning 1 0 Rosetta 4 1
BioBrick assembly standard 0 1 Vector NTI 3 5
Measurement, functional composition, data exchange Primer3 3 3
RPU 0 1 Mathematica 2 5
Electronic datasheets 0 1 Mfold 1 2
Visual datasheets 0 1 Gene Designer 1 2
DNA synthesis Blast 1 1
Commercial, short oligos 9 4 J5 DNA Assembly 1 1
Commercial, gene size (>500bp) 4 3 Vector Editor 1 1
In-house, gene-size(>500 bp) 3 2 GenoCAD 1 1
In-house, short oligos 1 4 Cell Designer 1 0
DNA sequencing ClothoCAD 1 0
Commercial 8 3 iBioSim 1 0
In-house 2 4 Gene Design 1 0
Culture technique ProtoBiocompiler 1 0
LB broth or agar 10 3 SimBiology 1 0
37°C incubator 10 3 SnapGene 1 0
Antibiotic selection 9 4 TinkerCell 1 0
Glycerol freezing 8 3 GenomeCompiler 0 1
30°C incubator 7 3 GEntle 0 1
Colorimetric medium 4 2 GLAMM 0 1
Other tools, reagents and methods COPASI 0 1
PCR 9 5 DeviceEditor 0 1
GFP reporters 7 4 Lasegene-DNA Star 0 1
Non-GFP reporters 6 4 RBS Calculator 0 1
Directed evolution 3 2
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granted patents and pending patent applications are
relevant to this method, including US Patents 7,723,077
and 7,776,532, US Applications 2010/0184187 and 2010/
0311126, and International Application PCT/US2006/
031214. Although the exclusive period for these patentsis expected to extend through at least 2026, access to
the Gibson assembly method has been made available
through a non-exclusive licensing agreement between
Synthetic Genomics, Inc. and New England BioLabs,
Inc. [41]. As such, components may be purchased from
New England BioLabs, Inc., albeit with significant
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for the sole benefit of the purchaser only” [42]. Those
desiring additional rights to the Gibson assembly
method, for example to manufacture commercial prod-
ucts, must contact Synthetic Genomics, Inc. directly.
Still other technologies that survey respondents consider
enabling for the field of synthetic biology are heavily pa-
tent protected and the ability of researchers to access these
technologies through licensing is less clear. For example,
the majority of survey respondents indicated current or
past use of GFP or non-GFP reporter molecules (Figure 5).
Fluorescent proteins are commonly used as genetically
encoded reporter molecules that enable researchers to
observe the activity of particular genetic elements and bio-
molecules inside live cells or tissues. One of the founda-
tional patents covering uses of GFP (US 5,491,084) is due
to expire in September 2013. However, the exclusivity pe-
riods for other foundational patents on GFP and its uses
are expected to continue for a number of years (e.g., US
5,741,668, US 6,146,826, EP 0 759 170 B1). Furthermore,
there are literally hundreds, if not thousands, of issued
patents covering variants of GFP and their uses. For ex-
ample, a search of CAMBIA’s Patent Lens (http://www.
patentlens.net) for the term “green fluorescent protein” in
the same claim [i.e., Expert Search of (green near/2 fluor-
escent) and (fluorescent near/2 protein) and (green near/2
protein) in claims] yielded 770 granted US patents and
256 granted European patents. Similar searches for yellow
fluorescent protein, red fluorescent protein, and blue
fluorescent protein yielded over 400 patents granted in the
US and Europe. The large number of patents covering var-
iants of GFP and their uses presents a considerable chal-
lenge to synthetic biology researchers who wish to use
fluorescent reporters in creating standards for characteriz-
ing biological parts and devices, such as the Relative Pro-
moter Unit (discussed below). Some relief to navigating
this thicket of patents may be available through negotiat-
ing a license agreement with Life Technologies or GE
Healthcare. For example, the ATCC has recently an-
nounced that they have secured a license agreement that
enables them to distribute GFP-containing biological ma-
terials to non-commercial and government researchers
[43]. However, for-profit customers must have a separate
license with Life Technologies or GE Healthcare to obtain
and use these materials.
In addition to the observations noted above, the survey
results indicate several trends for the use of technologies
by synthetic biology researchers. The majority of survey
respondents reported that they used biological parts
from or contributed parts to publicly available registries
(Figure 1) as well as private registries maintained within
individual laboratories (Figure 2). Among the most
widely used publicly available registries were the iGEM
Registry, the ATCC, and Addgene. These registries, aswell as many of the others listed in the survey, provide
researchers with tangible materials (e.g., cultures, plas-
mids, and other reagents) as well as information relevant
to the material (e.g., source, nucleic acid sequence, per-
formance specifications). From a technical perspective,
public registries are useful only to the degree that the
biological materials contained within are reliable and ac-
curately described. Towards that end, several publicly
available registries have undertaken steps to curate the
parts received and to verify nucleic acid sequence infor-
mation. From an intellectual property perspective, access
to materials from public registries is limited not only by
considerations of patent protection, but also by the
terms of material transfer agreements or other contracts
that may govern the transfer of tangible materials. Regis-
tries of biological parts such as the SynBERC registry,
the JBEI-ICE Public, and the BIOFAB currently provide
information only. To the extent that the genetically-
encoded materials described in these registries may be
readily synthesized from the sequence information pro-
vided, use of these materials is limited primarily by con-
siderations of patent protection. Although the SynBERC
and JBEI-ICE Public registries currently indicate whether
the material is “encumbered” or “not encumbered,” no
other information is provided to assist researchers wish-
ing to use these materials with identifying relevant pat-
ents. As for private registries, many survey respondents
indicated that they shared materials with others and that
they distributed materials by direct transfer as well as
through publicly available registries. The types of mate-
rials maintained in private registries and the terms for
their transfer were not queried in this survey, though
considerations of patent protection and possibly add-
itional contract terms would be relevant to use of mate-
rials from private registries as well.
Not all of the technologies queried in this survey were
used by the majority of survey participants. Unlike the
high usage rates reported for physical assembly stan-
dards and methods (Figure 3, Table 2), relatively few sur-
vey participants indicated current or past use of
standards and methods for measurement, functional
composition, and data exchange (Figure 4). One possibil-
ity that could account for such relatively low usage rates
is that some types of standards and methods have been
introduced only recently. For example, the EOU has
been presented at meetings as early as 2010 [44], but an
initial formal description and example applications of
the EOU have only recently been published [45,46]. An-
other possibility that could account for the relatively low
usage rate is that some types of standards and methods
require tools that are not readily licensed by industry.
For example, the RPU requires measurement of fluores-
cent reporter molecules [47] and it may be necessary to
work through the patent thicket surrounding uses of
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possible. Finally, it may also be that some technologies
identified in this survey are useful to only a subset of
survey respondents. The synthetic biology research com-
munity is comprised of diverse group of individuals with
varied interests and goals. As such, the technologies that
are considered vitally important for the work of some re-
searchers may not be used at all by others.
To the extent that one or more patented technologies
could eventually become widely adopted as a standard in
the field, it may be advisable for the synthetic biology re-
search community to consider creating more formal
organizational structures and to articulate policies and
best practices for the disclosure and licensing of pat-
ented technologies. Although standardization in syn-
thetic biology is still at a relatively young stage [48,49],
there are indications that the patent landscape is becom-
ing quite complex [50]. To mitigate potential difficulties
in the development and implementation of standards
using patented technologies, the field of synthetic biol-
ogy could benefit from the lessons learned by the
information and communications technologies (ICT) in-
dustry, where a multitude of patented technologies have
been incorporated into standards [51]. There, the cre-
ation of standards development organizations with for-
mal policies requiring fair, reasonable and non-
discriminatory (F/RAND) licensing terms have helped to
alleviate some of the problems the ICT industry has
faced in incorporating patented technologies into stan-
dards [52]. Because the creation of a standards develop-
ment organization is not a trivial undertaking and could
potentially raise antitrust concerns, it will be important
to work with counsel and abide by the recommendations
of governmental agencies [53,54].
Several limitations should be taken into account when
interpreting the results from this survey. First, this sur-
vey sampled only a fraction of the global synthetic biol-
ogy research community and included responses from
137 individuals, mostly from universities or research in-
stitutes within the United States. It is difficult to esti-
mate the number of individuals conducting research in
synthetic biology, though one study identified nearly
3,000 authors of scientific publications who were work-
ing on or writing about synthetic biology [55]. Given the
relatively small sample size, the survey results may be
subject to sampling bias (i.e., the demographics of the
survey respondents may not accurately reflect the demo-
graphics of the synthetic biology research community)
as well as potential reporting biases (i.e., the voluntary
reporting of this survey necessarily excludes those who
chose not to volunteer responses). A larger sampling of
the synthetic biology research community, with greater
representation of researchers outside of the United
States as well as researchers working in industry, mightprovide more balanced insight into the technologies
considered enabling for synthetic biology. Second, al-
though in-person interviews were conducted to identify
relevant technologies and create questions for the sur-
vey, the majority of responses were obtained through an
online format. Without an interactive format, such as
in-person or telephone interviews, to clarify any ambigu-
ities in the wording of survey questions, respondents
may have misunderstood some of the questions posed.
Third, the survey questions focused on the technologies
actually used by the synthetic biology research commu-
nity and did not explore the potential reasons underlying
why certain technologies were not used. Additional
questions that directly query whether intellectual prop-
erty rights covering certain technologies represented a
selection barrier against the use of those technologies
would also be informative. Finally, the results of this
survey reflect the experiences of synthetic biology re-
searchers at only one point in time. Re-administration of
surveys such as the one developed here could provide a
more complete view of the technologies that are consid-
ered enabling for synthetic biology as the field develops
over time.
Beyond facilitating the systematic investigation of
property rights, monitoring the enabling technologies of
synthetic biology could also help inform governmental
and non-governmental organizations in crafting policy
frameworks to address the safety and security concerns
raised by innovation in this field. Access to concrete data
on the technologies used by those working in basic and
applied synthetic biology research can be vital for mak-
ing changes to existing policies as well as for creating
new options for governance. For example, advances in
DNA synthesis technology and the resulting commercial
availability of larger synthetic DNA constructs [56] have
led to a shift from research conducted with recombinant
DNA to research conducted with synthetic nucleic acid
molecules. This shift in the technologies used for re-
search, in turn, has prompted the U.S. Department of
Health and Human Services to issue amended guidelines
for research involving recombinant or synthetic nucleic
acid molecules [57] and to develop recommendations
for a framework for synthetic nucleic acid screening
[58]. Similarly, monitoring the enabling technologies of
synthetic biology could help alert policy makers and
stakeholders to advances in technology that may exert a
comparable impact on innovation and research practices
in this field.
Conclusion
The survey results presented here provide insight into the
enabling technologies of synthetic biology. As innovation
in this field continues to advance we expect that the re-
agents, methods, and tools considered enabling for
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government, funding, and community organizations that
impact the regulation, patenting, and licensing of these
technologies are also subject to change. Because research
in synthetic biology is conducted across multiple institu-
tions in many countries, it will be important to adopt pol-
icies and practices that promote cross-institutional and
transnational exchange of ideas, data, and technology.
Moreover, because it is likely that useful applications
of synthetic biology will embody multiple patented in-
ventions, it will be important to create structures for
managing intellectual property rights that will pro-
mote access to the technologies used to comprise and
create commercially available products. By monitoring
the enabling technologies of synthetic biology and ad-
vancing policies and best practices for the patenting,
licensing and regulation of these technologies, our
hope is that the field will be better able to reach its
full potential to promote human health and preserve
the environment.
Methods
Survey design, distribution and analysis
We designed a web-based survey soliciting responses on
technologies that could be considered enabling by prac-
titioners engaged in synthetic biology research. For pur-
poses of the survey, enabling technologies were defined
as tools, reagents, and methods that, alone or in com-
bination with associated technologies, provide the means
to generate any new research tool or application in syn-
thetic biology. Technologies included in the survey were
compiled through review of the scientific literature and
personal interviews with synthetic biology researchers
from both academia and industry. Researchers working
in the field of synthetic biology were located by means
of personal references, professional networking, and re-
ferrals from synthetic biology organizations. For this first
survey, we focused on technologies used in research
1laboratories for the engineering of biological systems.
Given its seminal importance in promoting a sense of
community [59], we also examined the role of the iGEM
competition in fostering the adoption of certain tech-
nologies by synthetic biology researchers. Technologies
associated with safety and security were not within the
scope of this survey, nor were other potentially enabling
resources such as professional societies or technology
roadmaps.
We first piloted the survey by sending the question-
naire to researchers working in the laboratories of Drs.
Christina Smolke and Drew Endy in the Bioengineering
Department at Stanford University, and made adjust-
ments based on initial responses. We then sent the sur-
vey to members of the Synthetic Biology Engineering
Resource Center (SynBERC) and made further adjust-ments based on responses received by Days 6 and 19.
On Day 19 and at various times thereafter, a link to the
survey was forwarded to additional researchers working
in the field of synthetic biology by the BioBricks Founda-
tion (BBF), a public benefit organization that represents
the public interest in the field of synthetic biology
(http://biobricks.org), the ERASynBio, a program for the
development and coordination of synthetic biology in
the European Research Area (http://www.erasynbio.eu),
the iGEM Foundation, a public benefit organization that
organizes the iGEM competition (http://igem.org), the
organizers of SynBioBeta, an industry conference for
synthetic biology startup companies (http://synbiobeta.
com), and individuals working in community biolabs.
The survey was available via an interactive website
(http://www.surveymonkey.com) or as a Word docu-
ment directly from the authors, and the responses
reported were collected from August 31, 2012 through
January 30, 2013. Instructions provided at the beginning
of the survey encouraged respondents to answer the
questions based on their own experience and perspec-
tive. A PDF file of the survey questions is available as
Additional file 1.
Questionnaire data were exported into Microsoft Excel
for analysis and only valid responses were evaluated (i.e.,
only responses to the specific questions were included in
each analysis). Analyses that involved comparison of
researchers in academia and industry included only re-
sponses from survey participants that worked exclusively
in a non-commercial or commercial setting. Survey par-
ticipants were considered to be working in a non-
commercial setting if they indicated that they worked in
a college or university, research institute, government la-
boratory, or were independent (e.g., citizen scientist,
amateur biologist, etc.). Survey participants were consid-
ered to be working in a commercial setting if they indi-
cated that they worked in a for-profit company of any
size. Statistical significance was evaluated using Fisher’s
exact test over binary contingency tables [60].
Registries of natural or engineered biological materials or
information
Eleven publicly available registries were listed in Ques-
tion 3 throughout the duration of the survey: the iGEM
Registry (http://partsregistry.org), the JBEI-ICE Public
(https://public-registry.jbei.org), the SynBERC Registry
(https://registry.synberc.org), Addgene (http://www.
addgene.org), the DNASU Plasmid Repository (http://
dnasu.asu.edu/DNASU/Home.jsp), the DF/HCC Plas-
mID Repository (http://plasmid.med.harvard.edu/PLAS-
MID), the ATCC (http://www.atcc.org), the CGSC
(http://cgsc.biology.yale.edu), the EUROSCARF (http://
web.uni-frankfurt.de/fb15/mikro/euroscarf/index.html),
the Félix d’Hérelle Reference Center for Bacterial Viruses
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ARS/NRRL culture collection (http://nrrl.ncaur.usda.gov).
This group of publicly available registries includes both
registries that distribute tangible materials (e.g., cell lines,
plasmids, DNA binding proteins) and registries that serve
solely as repositories of information (e.g., DNA se-
quences, plasmid construction, performance specifica-
tions). Two additional publicly available registries were
added to the list for Question 3 after the collection of
85 responses, based on free text responses – the BCCM
(http://bccm.belspo.be/index.php) and the DSMZ
(http://www.dsmz.de).
Physical assembly standards and methods
Sixteen physical assembly standards and methods were
listed in Question 6 throughout the duration of the survey:
the original BioBrick assembly standard (BBF RFC 10) [61],
the BglBrick assembly standard (BBF RFC 21) [62], the
BioFusion standard (BBF RFC 23) [63], Freiberg standard
(BBF RFC 25) [64], the AarI cloning standard (BBF RFC
28) [65], the BioBytes assembly standard (BBF RFC 47)
[17], Circular Polymerase Extension Cloning (CPEC) [66],
DNA assembler [67], Gateway recombinatorial cloning
[68], Gibson assembly [40], GoldenBraid assembly [69],
GoldenGate shuffling [70], Modular Cloning (MoClo) [71],
Seamless Ligation Cloning Extract (SLICE) [72], Sequence
and Ligase Independent Cloning (SLIC) [73], and de novo
DNA synthesis [74]. Two additional physical assembly
methods were added to the list in Question 6 after the col-
lection of 52 responses based on free text responses –
Polymerase Incomplete Primer Extension (PIPE) [75] and
Uracil Specific Excision Reagent (USER) [76].
Tools for measurement, functional composition and data
exchange
Tools supporting functional composition of genetic
objects, measurement of intracellular molecular
activities, and data exchange were listed in Survey
Questions 7 and 8. Measurement tools included Poly-
merase Per Second (PoPS) [77], relative promoter unit
(RPU) [47], relative mammalian promoter unit
(RMPU) [78], functional composition tools included
the expression operating unit (EOU) [45], and data
exchange tools included Synthetic Biology Open Lan-
guage (SBOL) [79], SBOL Visual (SBOLv) [80,81], and
visual or electronic data sheets for biological parts
and devices [82,83].
Additional tools, methods and reagents
Additional tools, reagents, and methods that survey
participants could consider enabling were listed in
Survey Question 9. Genomic databases included the
DNA Databank of Japan (http://www.ddbj.nig.ac.jp),
European Nucleotide Archive (http://www.ebi.ac.uk/ena), GenBank (http://www.ncbi.nlm.nih.gov/genbank),
e!EnsemblGenomes (http://www.ensemblgenomes.org),
and MicrobesOnline (http://www.microbesonline.org).
Tools for searching, alignment, and analysis of DNA
sequences such as BLAST [84], ClustalW2 [85], and
OligoCalc [86], respectively, as well as commercial
and in-house methods for DNA synthesis [74] and
DNA sequencing [87] were also included. Long-
established cell culture technologies included anti-
biotic selection, temperature selection, lysogeny broth
(a.k.a., Luria-Bertani medium or LB medium) [37,88],
colorimetric media [89], and glycerol freezing of bac-
terial strains [38,39]. More recently established tools
such as PCR [10,11], fluorescent reporter molecules
[90], and directed evolution [91] were also included.Software tools
Thirty software tools, many of which have been recently
reviewed [92], were listed in Question 10 throughout the
duration of the survey: ApE (http://biologylabs.utah.edu/
jorgensen/wayned/ape), BioJADE (http://web.mit.edu/jago
ler/www/biojade), BioNetCAD (http://www.sysdiag.cnrs.fr/
BioNetCAD), Cell Designer (http://celldesigner.org),
ClothoCAD (http://www.clothocad.org), COPASI (http://
www.copasi.org), DeviceEditor (replaced by AutoBioCAD;
http://j5.jbei.org/index.php/Main_Page), Eugene (http://
eugenecad.org), GEC (http://research.microsoft.com/en-us/
projects/gec), Gene Designer (https://www.dna20.com/
genedesigner2), GeneDesign (http://www.genedesign.org),
GenoCAD (http://www.genocad.org), Genetdes (http://jara
millolab.issb.genopole.fr/display/sbsite/Download), GLAMM
(http://glamm.lbl.gov), iBioSim (http://www.async.ece.utah.







com/Proto/Proto.html), RBS Calculator (https://salis.psu.
edu/software), Rosetta (http://www.rosettacommons.org),
RoVerGeNe (http://iasi.bu.edu/~batt/rovergene/rovergene.
htm), SimBiology - MATLAB (http://www.mathworks.com/
products/simbiology), SynBioSS (http://www.synbioss.org),
TinkerCell (http://www.tinkercell.com), VectorEditor (http://
j5.jbei.org/index.php/Main_Page), and Vector NTI (http://
www.invitrogen.com/site/us/en/home/Products-and-Servi
ces/Applications/Cloning/vector-nti-software.html). Three
additional software tools were added to the list for
Question 10 after the collection of 51 responses based
on free text responses – GenomeCompiler (http://www.
genomecompiler.com), GENtle (http://gentle.magnusman
ske.de), and SnapGene (http://www.snapgene.com).
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